The shuttered Trump Taj Mahal casino in Atlantic City has found a buyer.
The new owner will be a group of investors led by Hard Rock International, the company behind Hard Rock Cafe.
President Trump once operated the hotel, but financed the project with junk bonds and could not cover their payments. He parted ways with the place in 2009.
Carl Icahn, who serves as an adviser in Trump’s administration, bought the place in early 2016 in a bid to save the failing establishment. The casino and hotel closed its doors in October 2016 after years of struggling to stay afloat.
Icahn Enterprises, which announced the sale Wednesday, said last year that it’s “lost almost $100 million trying to save the Taj.”
The Taj isn’t the only Atlantic City casino to fall on hard times. It was the fifth to close since 2014. As the city’s hallmark industry has failed to turn profitable, the local government has been strapped for cash and teetered on the brink of bankruptcy for months.
Top Casino Stocks To Invest In 2018: Occidental Petroleum Corporation(OXY)
- [By Garrett Cook]
Citi notes that presentations from producers (the bank specifically notes Anadarko (NYSE: APC), Occidental Petroleum (NYSE: OXY), and Pioneer Natural Resources (NYSE: PXD)) showed a lack of commitment to enter 2017 hedge programs to lock in the economics for drilling.
- [By Ben Levisohn]
We have seen several dividend cuts in the recent past, including Anadarko Petroleum cutting its dividend by 81%…and we expect more companies to follow suit. Chesapeake Energy (CHK), ConocoPhillips (COP), Encana,Marathon Oil and Noble Energy (NBL) are among energy companies that have also cut dividends in the past 12 months, but dividend requirements even after several cuts will consume ~26% of 2016 estimated cash flow at current dividend rates (15% excluding Occidental Petroleum (OXY)) for the large cap E&Ps we cover. We believe most of the companies with a dividend yield of more than 1.5% should consider cutting the dividend and find the following companies more likely than not to reduce dividends:Apache (2.5% yield),Devon Energy (4%),Encana (1.5%) andMarathon Oil (2.5%). We believe Canadian Natural Resource (CNQ) (3.0%) is likely to maintain its dividend while Occidental (4.5%) has the financial strength to maintain or even increase the dividend…
- [By Paul Ausick]
Occidental Petroleum Corp. (NYSE: OXY) dropped about 1.6% Friday, to post a new 52-week low of $64.19 after closing at $65.25 on Thursday. The stock’s 52-week high is $78.48. Volume was about 15% below the daily average of around 4.7 million shares. The company had no specific news.
- [By Lee Jackson]
These companies also reported insider buying last week: Carrizo Oil and Gas Inc. (NASDAQ: CRZO), Medifast Inc. (NYSE: MED), Medley Capital Corp. (NYSE: MCC), Occidental Petroleum Corp. (NYSE: OXY) and Sothebys (NYSE: BID).
- [By Ben Levisohn]
Stocks that made the cut include General Motors (GM), Coca-Cola Company (KO), Occidental Petroleum (OXY), JPMorgan Chase (JPM), and General Electric (GE).
- [By Chris Lange]
Occidental Petroleum Corp.s (NYSE: OXY) short interest increased to 17.60 million shares from the previous reading of 15.53 million. Shares closed most recently at $66.90, in a 52-week range of $58.24 to $78.48.
Top Casino Stocks To Invest In 2018: Vaalco Energy Inc(EGY)
- [By Monica Gerson]
VAALCO Energy, Inc. (NYSE: EGY) is expected to post a quarterly loss at $0.11 per share on revenue of $18.59 million.
B2Gold Corp (NYSE: BTG) is estimated to post its quarterly earnings at $0.00 per share on revenue of $135.84 million.
Top Casino Stocks To Invest In 2018: Regeneron Pharmaceuticals, Inc.(REGN)
- [By Ben Levisohn]
It hasn’t been an easy time for investors inRegeneron Pharmaceuticals (REGN) recently…and today’s price action is likely to reinforce the sense of whiplash they must be feeling.
Agence France-Presse/Getty Images
What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.
Fast forward to this afternoon, and and now they’re up nearly 3%. Credit Suisse analyst Alethia Young and team explain why the injunction outweighs the earnings:
Company issued Eylea guidance for 2017- they guided single digit
percentage growth over 2016. Consensus had been for 12% growth and we
had modeled 11% growth.
EPS for 4Q came in at $3.04 in line with $3.04 consensus. Since the company has already provided OpEx guidance for 2017 and the Eylea 4Q estimate ahead of today we think earnings are less of a focus.
We are curious where in the single digit percentage growth for Eylea the company means- 9% YoY growth wouldnt be too far from consensus vs. 3%
As we wrote last night, we would expect shares to trade up due to the injunction stay. We would expect shares to be up 2-4% from the injunction stay, but the effect might be muted somewhat by the Eylea guide. We would guess shares might be up 1 to 3% today.
Shares ofRegeneron Pharmaceuticals have gained 2.8% to $363.04 at 1:57 p.m. today, while the iS
- [By Johanna Bennett]
Shares of biotechnology giant Regeneron Pharmaceuticals (REGN) have climbed more than 4% today after Piper Jaffray analyst Ed Tenthoff upgraded the stock from a neutral to an overweight, with a $446 price target.
The upgrade comes just a few days after the drug maker released soft guidance for 2017 and forecasts called for slowing sales of the eye drug Eylea.
But Piper Jaffrays Tenthoff argues that anticipated approvals and deep pipeline should drive long-term value. Of particular importance: the atopic dermatitis drug Dupixent (dupilumab).
We are confident in FDA approval of Dupixent (dupilumab) in moderate-to-severe atopic dermatitis by the March 29th PDUFA date and in Europe in late 2017. The Phase III LIBERTY ASTHMA QUEST study has fully enrolled 1,858 persistent asthma patients to 200mg and 300mg subcu Dupixent q2W. We look for data this year to enable an sBLA submission by YE:17. Regeneron is conducting two Phase III trials in nasal polyps and will initiate Phase III pediatric atopic dermatitis and asthma trials. The company will report data from a Phase II eosinophilic esophagitis study in 1H:17 and begin a Phase II food allergy study in 2H:17. The FDA has deemed Sanofi’s Le Trait facility “acceptable”. As a result, we anticipate the partners will refile on Kevzara (sarilumab) and could gain approval in 2Q:17. These two launches should turn Regeneron’s antibody alliance with Sanofi profitable.
Todays news is the latest development in what has been a volatile time the drug maker. The shares have fallen sharply over the during the last three months, the result of a patent suit with Amgen (AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldnt be able to sell in the U.S. , But last week, a judge granted a stay that would allow Regeneron to sell Praluent. It also fueled a pop in its shares.
The next day, however, Regeneron reported earnings, and while profits o
- [By Ben Levisohn]
After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:
- [By Todd Campbell, Demitrios Kalogeropoulos, and Reuben Gregg Brewer]
In the case of these three stocks, however, it may be worth taking a gamble. Our contributors think catalysts at Regeneron Pharmaceuticals (NASDAQ:REGN), Royal Dutch Shell (NYSE:RDS-B), and United Parcel Service (NYSE:UPS) can get them back to their winning ways. Read on to find out if these down-and-out stocks are right for your portfolio.